Furthermore, the NAS/melatonin ratio showed robust discriminatory ability (AUC: 0.995, 95% CI: 0.980–1.011) for distinguishing hormone receptor-positive BC patients from controls (Figure 12). This evidence concerns the gene NR4A1 and breast cancer.